The state of Connecticut currently has 15 active clinical trials seeking participants for Alzheimer's Disease research studies. These trials are conducted in various cities, including New Haven, Hartford, Farmington and Stamford.
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Recruiting
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). This study will also evaluate the long-term safety and tolerabili... Read More
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
02/06/2024
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
Recruiting
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/24/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Alzheimer's Disease
Plasma P-tau2017 and Quantitative Amyloid PET Imaging
Recruiting
The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels.
Gender:
All
Ages:
70 years and above
Trial Updated:
12/07/2021
Locations: Invicro, New Haven, Connecticut
Conditions: Alzheimer Disease